Epigenetic therapy: Use of agents targeting deacetylation and methylation in cancer management Journal Article
| Authors: | Ho, A. S.; Turcan, S.; Chan, T. A. |
| Article Title: | Epigenetic therapy: Use of agents targeting deacetylation and methylation in cancer management |
| Abstract: | The emergence of epigenetic mechanisms as key regulators of gene expression has led to dramatic advances in understanding cancer biology. Driven by complex layers that include aberrant DNA methylation and histone modification, epigenetic aberrations have emerged as critical processes that disrupt cellular machinery and homeostasis. Recent discoveries have already translated into successful clinical trials and improved patient care, with several agents approved for hematologic disease and others undergoing study. As the field matures, substantial challenges persist that will require resolution. These include the need to decipher more fully the interplay between the epigenetic and genetic machinery, patient selection and improving treatment efficacy in solid tumors, and optimizing combination therapies to counteract chemoresistance and minimize adverse effects. Here, we review recent progress in epigenetic treatments and consider their implications for future cancer therapy. © 2013 Ho et al, publisher and licensee Dove Medical Press Ltd. |
| Keywords: | treatment outcome; unclassified drug; acute granulocytic leukemia; methylation; fatigue; neutropenia; review; placebo; diarrhea; drug efficacy; drug safety; nonhuman; side effect; antineoplastic agent; anorexia; anemia; bone marrow suppression; transcription initiation; nausea; thrombocytopenia; genetic association; cancer therapy; dna methylation; hodgkin disease; carcinogenesis; lymphocytopenia; cutaneous t cell lymphoma; myelodysplastic syndrome; transcription regulation; drug mechanism; epigenetics; histone; cardiotoxicity; drug response; transcription; vorinostat; malignant neoplastic disease; 5 aza 2' deoxycytidine; large cell lymphoma; hypercholesterolemia; tumor; panobinostat; romidepsin; follicular lymphoma; azacitidine; deacetylation; acetylation; demethylation; molecularly targeted therapy; mocetinostat; histone methylation; t wave; histone acetylation; chemotherapy induced nausea and vomiting; 3 deazaneplanocin a; jq 1 |
| Journal Title: | OncoTargets and Therapy |
| Volume: | 6 |
| ISSN: | 1178-6930 |
| Publisher: | Dove Medical Press Ltd |
| Date Published: | 2013-01-01 |
| Start Page: | 223 |
| End Page: | 232 |
| Language: | English |
| PROVIDER: | scopus |
| PMCID: | PMC3615839 |
| PUBMED: | 23569385 |
| DOI: | 10.2147/ott.s34680 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 May 2013" - ":doi 10.2147/OTT.S34680" - ": Chemicals/CAS3 deazaneplanocin A, 102052-95-9; 5 aza 2' deoxycytidine, 2353-33-5; azacitidine, 320-67-2, 52934-49-3; mocetinostat, 726169-73-9, 944537-89-7; panobinostat, 404950-80-7; romidepsin, 128517-07-7; vorinostat, 149647-78-9" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work